EUVIMEDEUVIMED entdecken
Crossref

Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019–2020)

Sydney R Dana, Stephanie D Nichols, Kenneth L McCall, Brian J Piper

Journal of Studies on Alcohol and Drugs · 2024

DOI: 10.15288/jsad.22-00373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Studies on Alcohol and Drugs, 2024. Verfasst von Sydney R Dana und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The purpose of this study was to analyze buprenorphine prescribing across states in Medicaid patients during 2019-2020. METHOD: Buprenorphine prescriptions per Medicaid enrollee per state were calculated for 2019 and 2020. Data analysis was conducted with buprenorphine formulations that are approved by the U.S. Food & Drug Administration for opioid use disorder (OUD; including generic and brand name formulations of buprenorphine mono product and buprenorphine/naloxone combination products) using Microsoft Excel. The totals of mono product buprenorphine were divided over the total of combination buprenorphine/naloxone in 2019 and 2020 to obtain the ratio of mono/combo. Formulations of buprenorphine indicated for pain were excluded. States outside 95% confidence intervals (1.96 standard deviations above and below the mean) were considered statistically significant. RESULTS: The overall change in buprenorphine prescribing between 2019 and 2020 was modest (+3.6%) but highly variable, with more than a 10% increase in 17 states (Iowa = +100.5%, p < .05) but more than a 10% decrease in 9 states (Alabama = -68.5%, p < .05). Total amount reimbursed in 2019 increased (+9.9%) to $1.42 billion in 2020. Branded formulations accounted for two fifths (39.5%) of prescribing but more than two thirds (66.8%) of spending in 2020. CONCLUSIONS: The COVID-19 pandemic exacerbated state-level disparities in buprenorphine prescribing for OUD among Medicaid patients. Legislation expanding buprenorphine-waivered providers and Medicaid expansion may have contributed to the statistically significant changes in state buprenorphine prescriptions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersUnited StatesHumansMedicaidPandemicsNaloxoneAnalgesics, Opioid

Substanzen

BuprenorphineNaloxoneAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Medical Education, Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania.
  • School of Pharmacy, University of New England, Portland, Maine.
  • Department of Pharmacy Practice, Binghamton University, Johnson City, New York.
  • Center for Pharmacy Innovation and Outcomes, Danville, Pennsylvania.

Zitieren

APA

Dana, S. R., Nichols, S. D., McCall, K. L., & Piper, B. J. (2024). Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019–2020). Journal of Studies on Alcohol and Drugs. https://doi.org/10.15288/jsad.22-00373

Vancouver

Dana SR, Nichols SD, McCall KL, Piper BJ. Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019–2020). Journal of Studies on Alcohol and Drugs. 2024. doi:10.15288/jsad.22-00373

BibTeX
@article{Dana2024,
  author = {Dana, Sydney R and Nichols, Stephanie D and McCall, Kenneth L and Piper, Brian J},
  title = {Pronounced State-Level Disparities in Medicaid Prescribing of Buprenorphine for Opioid Use Disorder (2019–2020)},
  journal = {Journal of Studies on Alcohol and Drugs},
  year = {2024},
  doi = {10.15288/jsad.22-00373}
}
Kostenlos starten →